Journal of Hepatology
Volume 48 , Pages S104-S112 , 2008

Non-alcoholic fatty liver disease: The mist gradually clears

  • Nimantha Mark Wilfred de Alwis
    • ,
  • Christopher Paul Day

      Affiliations

    • Corresponding Author InformationCorresponding author. Address: School of Clinical Medical Sciences, Floor 4 William Leech Building, The Medical School, Framington Place, Newcastle upon Tyne NE2 4HH, United Kingdom. Tel.: +44 191 222 7043; fax: +44 191 222 0723.

  • Image Result

    Natural history of NAFLD over 8–13years. HCC, hepatocellular carcinoma; OLTx, liver transplantation. Source Refs. .

    Natural history of NAFLD over 8–13years. HCC, hepatocellular carcinoma; OLTx, liver transplantation. Source Refs. .

☆ C.P. Day is currently Chief investigator on a Sanofi-Aventis sponsored trial of rimonabant in non-alcoholic fatty liver disease. He has consultancies with Pfizer, UK Ltd., GlaxoSmithKline and Astellas with respect to developing therapies for NAFLD. He has received funding from ROCHE products UK to perform a study of orlistat in non-alcoholic fatty liver disease. He declares that he received funding from the Medical Research Council, UK, The Wellcome Trust, The Department of Health, UK and the Commonwealth Scholarship Commission.

PII: S0168-8278(08)00055-X

doi: 10.1016/j.jhep.2008.01.009

Journal of Hepatology
Volume 48 , Pages S104-S112 , 2008

Article Tools

* Image Usage & Resolution